TLDR
- First quarter earnings per share reached $7.79, surpassing analyst expectations of $7.60
- Quarterly revenue climbed 5% to $68.5 billion, exceeding the $66.3 billion forecast
- Company increased 2026 full-year EPS outlook to minimum $30.35, a $0.10 boost
- Shares declined approximately 3% despite positive results, as pharmacy segment concerns emerged
- Leadership transition underway with David Cordani retiring July 1; Brian Evanko named successor
The health insurance giant delivered impressive first-quarter results, yet investors responded with skepticism. Despite exceeding earnings and revenue projections while raising annual forecasts, the company witnessed its shares decline.
CIGNA $CI Q1’26 EARNINGS HIGHLIGHTS
🔹 Adj. Revenue: $68.52B (Est. $66.24B) 🟢; +5% y/y
🔹 Adj. Operating EPS: $7.79 (Est. $7.61) 🟢
🔹 Healthcare Adj. Revenue: $11.48B (Est. $11.37B) 🟢
🔹 Healthcare Medical Care Ratio: 79.8% (Est. 81.0%) 🟢
🔹 FY Adj. Operating EPS Guide: At…— Wall St Engine (@wallstengine) April 30, 2026
First quarter adjusted earnings per share registered at $7.79, representing an increase from the prior year’s $6.74 and surpassing Street expectations of $7.60. Total revenue reached $68.5 billion, marking a 5% year-over-year gain and beating the $66.3 billion projection.
Management elevated its 2026 full-year EPS projection to a minimum of $30.35, representing a $0.10 improvement over previous estimates. This updated midpoint marginally exceeds the analyst consensus figure of $30.33.
Nonetheless, shares tumbled approximately 3% to trade near $283 during morning sessions.
Adjusted operational income expanded 12% to reach $2.1 billion, up from $1.8 billion during the first quarter of 2025. Performance improvements were primarily attributed to the Cigna Healthcare and Evernorth Health Services divisions.
The Cigna Healthcare segment saw pre-tax adjusted operational income surge 18% to $1.5 billion. The medical care ratio showed improvement at 79.8%, compared to 82.2% in the corresponding period last year.
Evernorth delivered adjusted revenues of $58.4 billion, representing a 9% annual increase. Income from Specialty and Care Services segments jumped 20% to $1.1 billion.
Pharmacy Business Under the Microscope
The pharmacy benefit manager division represented the quarter’s soft spot. TD Cowen analyst Charles Rhyee identified it as the sole weak point in an otherwise solid quarterly performance, though emphasized it wasn’t unexpected given comparable challenges at UnitedHealth and Elevance Health. His firm maintained a Buy recommendation with a $338 target price.
Leerink Partners analyst Whit Mayo maintained a Market Perform stance, noting that while results appear satisfactory, nothing stands out as especially noteworthy or unexpected.
The company has been restructuring its PBM operations since autumn, transitioning toward a model eliminating rebates in response to regulatory demands and public scrutiny regarding pharmaceutical pricing strategies.
Leadership Transition Adds Uncertainty
This past February, the company’s Express Scripts unit became the initial major PBM to reach a settlement with the Federal Trade Commission regarding insulin pricing litigation. The agreement involved no admission of wrongdoing and aligned with the previously announced rebate-free approach.
Simultaneously, the organization is preparing for a leadership succession. Chief Executive David Cordani will retire effective July 1, with Chief Operating Officer Brian Evanko assuming the top position.
The convergence of business model restructuring, executive succession, and tempered analyst sentiment clarifies why a quarter featuring both earnings beats and raised guidance failed to generate positive stock momentum.
The most encouraging aspects of the quarterly report included the enhanced medical care ratio and robust organic expansion within specialty business segments.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
